Clinical Trial Update: Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of inhaled aviptadil acetate (ZYESAMI) for severe COVID-19 was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• ZYESAMI (aviptadil acetate)

Snippet

Sponsor: APR Applied Pharma Research s.a. | Conditions: SARS-CoV 2, COVID | Phase 2, Phase 3 | Status: TERMINATED